Prospective Observational Evaluation of the Time-Dependency of Adalimumab Immunogenicity and Drug Concentration in Ulcerative Colitis Patients: the POETIC II Study.
Sivan HarnikChaya Mushka AbitbolOla Haj NatourMiri YavzoriElla FudimOrit PicardTimna NaftaliEfrat BroideAyal HirschLimor SelingerEyal ShacharDoron YablecovitchAhmad AlbsheshDaniel CoscasUri KopylovRami EliakimShomron Ben-HorinBella UngarPublished in: Journal of Crohn's & colitis (2023)
Loss of response to adalimumab therapy was significantly more common in the Ulcerative Colitis compared to the Crohn's disease cohort and was driven by a higher rate of non-immunogenic, pharmacodynamic parameters.